Cargando…
Efficacy of Pembrolizumab and Nivolumab in Crossing the Blood Brain Barrier
Metastatic brain tumors are the leading cause of central nervous system malignancies in adults, surpassing primary central nervous system with non-small cell lung cancer, accounting for more than 50% of all cases. The emergence of immunotherapies such as antibodies targeting the immune check points...
Autores principales: | Abid, Haisam, Watthanasuntorn, Kanramon, Shah, Omid, Gnanajothy, Rosana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6559690/ https://www.ncbi.nlm.nih.gov/pubmed/31245230 http://dx.doi.org/10.7759/cureus.4446 |
Ejemplares similares
-
SUN-LB036 Diabetic Ketoacidosis: A Rare Side Effect of Nivolumab Induced Insulin Dependent Diabetes Mellitus
por: Abid, Haisam, et al.
Publicado: (2019) -
Severe Hyponatremia Due to Cisplatin-induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone
por: Abid, Haisam, et al.
Publicado: (2019) -
Osteoclast Giant Cell Tumor of Pancreas: A Case Report and Literature Review
por: Abid, Haisam, et al.
Publicado: (2019) -
Into the Clinic With Nivolumab and Pembrolizumab
por: Shu, Catherine A., et al.
Publicado: (2016) -
Molecular Farming of Pembrolizumab and Nivolumab
por: Stark, Michael C., et al.
Publicado: (2023)